triciribine
Small moleculeexperimental
Triciribine is a cancer drug which was first synthesized in the 1970s and studied clinically in the 1980s and 1990s without success. Following the discovery in the early 2000s that the drug would be effective against tumours with hyperactivated Akt, it is now again under consideration in a variety of cancers. As PTX-200, the drug is currently in two early stage clinical trials in breast cancer and ovarian cancer being conducted by the small molecule drug development company Prescient Therapeutics. — Wikipedia
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2006 (NCT00642031)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serine/threonine-protein kinase AKTINHIBITOR
Serine/threonine-protein kinase AKT inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23- Mol. weight
- 400.29 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTriciribine ↗
- ChEMBLCHEMBL462018 ↗
Also known as
- 1,4,5,6,8-pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-o-phosphono-beta-d-ribofuranosyl)-
- 1,4,5,6,8-pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-beta-d-ribofuranosyl-
- 1,4,5,6,8-pentaazaacenaphthylene-3-amino-1,5-dihydro-5-methyl-1-beta-d-ribofuranosyl 5'-phosphate ester
- 3-amino-1,5-dihydro-5-methyl-i-beta-d-ribofuranosyl-1,4,5,6,8- pentaazaacenaphthylene
- 6-amino-4-methyl-8-(beta-d-ribofuranosyl)-(4h,8h)pyrrolo(4,3,2-de)pyrimido(4,5-c)pyridazine
- 6-arppp
- nsc 154020
- nsc-154020
- nsc 154120
- nsc 280594
- nsc-280594
- phosphate salt of tricyclic nucleoside
- phosphate salt of tricyclic nucleoside
- tcn-monophosphate
- tcnp
- tcn-p
- triciribine
- triciribine
- triciribine
- triciribine
- triciribine
- triciribine phosphate
- triciribine phosphate
- triciribine phosphate
- triciribine phosphate
- vqd-002
- vqd-002
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01690468 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2014 | Prescient Therapeutics, Ltd., University of South Florida |
| NCT01697293 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2012 | National Cancer Institute (NCI), Yeshiva University |
| NCT00642031 | Phase 1 | Aug 1, 2006 | Prescient Therapeutics, Ltd., University of Texas at Houston, VioQuest Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Prescient Therapeutics, Ltd. | For profit | 2 | 2 | 2 | 2006 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2012 |
| University of South Florida | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2006 |
| VioQuest Pharmaceuticals | For profit | 1 | 0 | 1 | 2006 |
| Yeshiva University | Academic/Hospital | 1 | 1 | 1 | 2012 |
6 organizations
Page 1 / 1